Role of glycosylation in hyperphosphorylation of tau in Alzheimer’s disease  by Liu, Fei et al.
Role of glycosylation in hyperphosphorylation of tau in
Alzheimer’s disease
Fei Liua, Tanweer Zaidia, Khalid Iqbala, Inge Grundke-Iqbala, Roberta K. Merkleb,
Cheng-Xin Gonga;
aDepartment of Neurochemistry, New York State Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island,
NY 10314, USA
bComplex Carbohydrate Research Center, the University of Georgia, 220 Riverbend Road, Athens, GA 30602, USA
Received 3 December 2001; revised 18 December 2001; accepted 19 December 2001
First published online 11 January 2002
Edited by Jesus Avila
Abstract In Alzheimer’s disease (AD) brain, microtubule-
associated protein tau is abnormally modified by hyperpho-
sphorylation and glycosylation, and is aggregated as neurofi-
brillary tangles of paired helical filaments. To investigate the role
of tau glycosylation in neurofibrillary pathology, we isolated
various pools of tau protein from AD brain which represent
different stages of tau pathology. We found that the non-
hyperphosphorylated tau from AD brain but not normal brain
tau was glycosylated. Monosaccharide composition analyses and
specific lectin blots suggested that the tau in AD brain was
glycosylated mainly through N-linkage. In vitro phosphorylation
indicated that the glycosylated tau was a better substrate for
cAMP-dependent protein kinase than the deglycosylated tau.
These results suggest that the glycosylation of tau is an early
abnormality that can facilitate the subsequent abnormal
hyperphosphorylation of tau in AD brain. ß 2002 Federation
of European Biochemical Societies. Published by Elsevier Sci-
ence B.V. All rights reserved.
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1. Introduction
Tau protein is one of the major microtubule-associated pro-
teins in neurons. Its normal function is to promote microtu-
bule assembly and stabilize microtubules. In Alzheimer’s dis-
ease (AD) brain, tau is abnormally hyperphosphorylated (AD
P-tau) and aggregates into paired helical ¢laments (PHF) in
a¡ected neurons [1^4]. Accumulation of PHF in the neuronal
cell bodies as neuro¢brillary tangles (NFT) is one of the his-
topathological hallmarks of AD. The number of NFT in the
brain correlates directly with the degree of dementia in AD
patients [5^7]. In addition to PHF, there is a pool of AD P-
tau in AD brain that is not aggregated into PHF [8]. Unlike
normal tau (N-tau) isolated from normal human brain tissue,
both PHF-tau and AD P-tau are unable to bind to micro-
tubules and promote their assembly. This ability is, however,
restored after the proteins are dephosphorylated with phos-
phatase [9^12]. In addition, AD brain also contains normal
level of non-hyperphosphorylated tau (AD-tau) [13]. Unlike
AD P-tau or PHF-tau, AD-tau has normal activity to pro-
mote microtubule assembly in vitro [9].
We have shown that unlike N-tau, AD P-tau and PHF-tau
are glycosylated besides abnormal hyperphosphorylation [12].
The glycosylation of PHF in AD brain was also con¢rmed
immunohistochemically by lectin staining [14]. The carbohy-
drate structures of isolated AD P-tau and PHF-tau have re-
cently been identi¢ed [15]. This aberrant glycosylation of AD
P-tau and PHF-tau is di¡erent from modi¢cation with O-
linked N-acetyl-D-glucosamine (O-GlcNAcylation), a novel
type of glycosylation recently found in bovine tau (B-tau) [16].
Post-translational modi¢cation by either glycosylation or
phosphorylation usually alters the protein con¢rmation, and
may consequently change its susceptibility to another modi¢-
cation and its biological activity. In the present study, we have
investigated the nature and the temporal sequence of the ab-
normal glycosylation and the abnormal hyperphosphorylation
of tau in AD. We found that the tau glycosylation is an early
abnormality of neuro¢brillary degeneration in AD, and that
the glycosylation of tau might facilitate its abnormal hyper-
phosphorylation in AD brain.
2. Materials and methods
2.1. Materials
The polyclonal antibodies 92e to bovine brain tau and R134d to
recombinant human brain tau were raised as previously reported [17].
The monoclonal antibodies Tau-1 and PHF-1 were gifts from Dr.
Lester Binder of Northwestern University (Chicago, IL, USA) and
Dr. Peter Davies of Albert Einstein College of Medicine (Bronx,
NY, USA), respectively. Polyclonal antibodies anti-tau[pS199], anti-
tau[pS214], anti-tau[pS262], anti-tau[pS396] and anti-tau[pS409] were
from Biosource International (Camarillo, CA, USA). Rabbit antise-
rum R145d was raised against a synthetic peptide corresponding to
residues 417^426 of tau with phosphorylated Ser422 [18]. Goat anti-
mouse IgG or anti-rabbit IgG conjugated with alkaline phosphatase,
biotin-conjugated APA, horseradish peroxidase^RCA and avidin-con-
jugated horseradish peroxidase were from Sigma (St. Louis, MO,
USA). Total Glycan Detection kit, Glycan Di¡erentiation kit which
contains digoxigenin-coupled GNA, MAA, SNA, PNA and DSA (see
Table 1), peptide-N-glycosidase F (PNGase F), O-glycosidase and
sialidase were purchased from Roche Diagnostic Corp. (Indianapolis,
IN, USA). The catalytic subunit of cAMP-dependent protein kinase
(PKA) was obtained from Sigma (St. Louis, MO, USA). DSA-
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coupled agarose was bought from EY laboratory (San Mateo, CA,
USA). Seize1 X Protein G Immunoprecipitation kit was from Pierce
(Rockford, IL, USA).
Autopsied human brain tissue used for this study was obtained
within 6 h post-mortem and stored in liquid nitrogen or a 380‡C
freezer until used. Both of the AD and age-matched non-neuropatho-
logical control brains were histopathologically con¢rmed and supplied
by brain banks.
2.2. Preparation of tau proteins
B-tau, N-tau and AD-tau were isolated as described previously
from 100 000Ug brain extracts by 2.5% perchloric acid treatment
and carboxymethyl chromatography using Millipore MemSep CM
10/10 disk [9]. AD P-tau and some preparations of AD-tau were
prepared from the 27 000Ug to 200 000Ug fraction of AD brain
homogenate with 8 M urea treatment and phosphocellulose chroma-
tography [8]. In some experiments, AD-tau and AD P-tau were puri-
¢ed with Seize1 X Immunoprecipitation kit (Pierce, IL, USA) accord-
ing to the manufacturer’s instruction, in which Tau-1 or a mixture of
anti-tau[pS199] and anti-tau[pS396] was chemically cross-linked with
protein G conjugated to agarose beads was used as immunoadsorb-
ent.
PHF-tau was isolated from cerebral cortex of AD brain by Iqbal’s
long procedure [19]. The protein was quantitated by modi¢ed Lowry
assay [20]. Immunoa⁄nity-puri¢ed PHF-tau was prepared by using
monoclonal antibody MC-1 as described previously [21].
2.3. Lectin and Western blot analysis
Tau samples were resolved by 10% SDS^polyacrylamide gel elec-
trophoresis (PAGE) as described originally by Laemmli [22], followed
by electroblotting to polyvinylidene di£uoride (PVDF) membranes
(Millipore, Bedford, MA, USA) for lectin blots and Western blots.
The detection of total glycans of tau proteins on PVDF membrane
was carried out according to the manufacturer’s instructions (Roche
Diagnostic Corp., Indianapolis, IN, USA). The nature of sugar moi-
eties attached to the tau proteins was identi¢ed by incubation of the
PVDF blots with various lectins (Table 1) which speci¢cally bind to
di¡erent sugar moieties. These lectins were pre-conjugated with digox-
igenin, horseradish peroxidase, or biotin. For some experiments, we
included speci¢c sugar in the lectin solution in order to speci¢cally
block the binding of the lectin to glycoproteins by competitive inhi-
bition. For this purpose, 0.3 M lactose was added to the APA and
MAA/SNA solution, 0.5 M K-methyl mannose to the GNA solution
and 0.5 M galactose to the PNA solution.
The quantity and phosphorylation state of tau on the blots were
con¢rmed by developing the blots with various phosphorylation-in-
dependent (92e and R134d) and -dependent (Tau-1, 12E8, PHF-1 and
R145) tau antibodies as described by us previously [23].
2.4. Monosaccharide composition analysis
The immunoa⁄nity-puri¢ed PHF-tau was hydrolyzed with 2 N
tri£uoroacetic acid at 100‡C for 4 h for the release of neutral and
amino sugars. Sialic acids were released by mild acid hydrolysis using
2 M acetic acid at 80‡C for 3 h. After hydrolysis, the samples were
dried using a centrifugal vacuum evaporator and were resuspended
with water. The samples were then subjected to Dionex high-pH
anion-exchange chromatography (HPAEC). The calibration standards
(0.5, 1.0 and 2.0 nmol each of fucose, N-acetyl-D-galactosamine (Gal-
NAc), GlcNAc, galactose, glucose and mannose for neutral and ami-
no sugars; 0.25, 0.5 and 1.0 nmol of N-acetyl neuraminic acid for
sialic acid) were hydrolyzed and analyzed in parallel with PHF-tau
samples.
2.5. In vitro deglycosylation and phosphorylation of AD-tau
When preparing the substrate for PKA, AD-tau (400 Wg) was ¢rst
diluted to a total volume of 4.0 ml with a deglycosylation bu¡er
containing 20 mM sodium phosphate, pH 7.2, 20 mM EDTA and
10 mM L-mercaptoethanol. The solution was heated in a 95‡C water
bath and then sonicated in a bath sonicator for 20 min each. The
sample was then divided into two parts, 2.0 ml each. Into one part,
PNGase F (6 U/ml), O-glycosidase (7.5 mU/ml) and sialidase (50 mU/
ml) were added. Into the other half, deionized water equal to the total
volume of the added enzymes was added. The two tubes were then
incubated at 37‡C overnight, followed by boiling and bath sonication
for 10 min each. The samples were centrifuged at 14 000Ug for 10 min
to remove any insoluble materials including the denatured enzymes.
The heat-stable tau was recovered from the supernatant. The latter
was concentrated from 2.0 ml to approximately 400 Wl by a speed
vacuum concentrator, followed by dialysis against 40 mM HEPES,
pH 7.2, 10 mM L-mercaptoethanol and 10 mM MgCl2. The deglyco-
sylated and control-treated AD-tau were stored at 320‡C until used.
The protein concentration of the samples was determined by the
Modi¢ed Lowry Method [20] and the success of the deglycosylation
was examined by Total Glycan Detection kit.
Two types of assay were employed for measuring the phosphoryla-
tion of AD P-tau. One was the conventional radioactive assay. AD-
tau (0.4 mg/ml) with and without pre-deglycosylation by glycosidases
was incubated at 30‡C in a phosphorylation reaction mixture contain-
ing 40 mM HEPES (pH 6.8), 10 mM L-mercaptoethanol, 1.0 mM
EGTA, 10 mM MgCl2, 0.1 mM [Q-32P]ATP and 20 Wg/ml PKA. After
various periods of incubation, an aliquot of the reaction mixture was
transferred onto a strip of Whatman 32 ET chromatography paper,
where the same volume of 20% trichloric acid and 5 mM ATP was
pre-spotted to stop the phosphorylation reaction. The incorporated
32Pi was then separated from the free [Q-32P]ATP by paper chroma-
tography [24], and the radioactivities were determined by Cerenkov
counting. For the second method to measure the phosphorylation of
AD-tau, the phosphorylation reaction was carried out as described
above except that [Q-32P]ATP was replaced by non-radioactive ATP.
The reaction was terminated by transferring the reaction mixture into
a tube containing hot (V90‡C) Tris-bu¡ered saline, followed by heat-
ing in a boiling water bath for 5 min. Then, the reaction product, i.e.
the phosphorylated tau, was quantitated by a radioimmuno-dot-blot
assay using a mixture of polyclonal antibodies anti-tau[pS214], anti-
tau[pS262] and anti-tau[pS409] (1:1000 dilution each) as primary anti-
body and 125I-labeled anti-rabbit IgG (0.1 Wg/ml) as secondary anti-
Table 1
Speci¢city and concentrations of lectins employed
Lectins (abbreviation) Binding speci¢city Conjugated with Concentration used (Wg/ml)
Agaricus bisporus agglutinin (ABA) L-Gal biotin 0.5
Abrus precatorius agglutinin (APA) L-Gal biotin 2.0
Concanavalin A (ConA) K-Man, K-Glc peroxidase 4.0
Datura stramonium agglutinin (DSA) GalL1,4GlcNAc and digoxigenin 1.0
GlcNAcL1,4GlcNAc
Erythrina corallodendron agglutinin (ECA) GalL1,4GalNAc biotin 2.0
Galanthus nivalis agglutinin (GNA) K-Man peroxidase 4.0
Lens culinaris agglutinin (LCA) K-Man biotin 2.0
Maackia amurensis agglutinin (MAA) SAK2,3Gal digoxigenin 5.0
Peanut agglutinin (PNA) GalL1,3GalNAc digoxigenin 10.0
Ricinus communis agglutinin (RCA) LGal (terminal) and peroxidase 5.0
GalL1,4GlcNAc
Sambucus nigra agglutinin (SNA) SAK2,6Gal digoxigenin 1.0
Tetragonolobus purpureaqs agglutinin (TGP) K-L-Fuc peroxidase 20.0
Ulex europaeus agglutinin (UEA I) K-L-Fuc peroxidase 40.0
Fuc: fucose; Gal: galactose; Glc: glucose; Man: mannose; SA: sialic acid.
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body. The radioimmunoreactivity of the blots was visualized and
quantitated by using a PhosphorImager (Fuji¢lm BAS-1500) and
TINA 2.0 software (raytest, IsotopenmeL gera«te GmbH).
3. Results
3.1. Tau glycosylation is an early abnormality of neuro¢brillary
degeneration in AD
Based on phosphorylation state, biological activity and sol-
ubility, tau in AD brain can be divided into three states, AD-
tau, AD P-tau and PHF-tau. These three states of tau appear
to represent various stages of tau pathology of AD. We,
therefore, ¢rst examined the glycosylation of these three states
of tau isolated from AD brain as well as tau protein isolated
from normal control human brain and, as a reference, bovine
brain. The quality of the tau preparations used was examined
by Western blots developed with various tau antibodies (Fig.
1A^E). Antibody 92e stained all tau preparations that dis-
played multiple tau bands due to multiple isoforms and var-
ious post-translational modi¢cations (Fig. 1A). As compared
with N-tau (lane 2) and AD-tau (lane 3), AD P-tau (lane 4)
had a slower mobility in SDS^PAGE due to the abnormal
hyperphosphorylation as reported previously [8]. PHF-tau
(lane 5) is well known to display as a smear due to aggrega-
tion. Antibody Tau-1, which recognizes N-tau but not hyper-
phosphorylated tau, only strongly stained B-tau, N-tau and
AD-tau (Fig. 1B). In contrast, 12E8, PHF-1 and R145, which
recognize tau only when it is phosphorylated at Ser262/
Ser356, Ser396/Ser404 and Ser422, respectively [23,25,26],
did not or only faintly stained AD-tau, but strongly stained
AD P-tau and PHF-tau (Fig. 1C^E).
To identify the glycosylation state of these tau preparations,
we employed various lectins to label tau transferred to PVDF
membrane. These lectins speci¢cally bind to di¡erent sugar
moieties of glycoproteins (Table 1) and, therefore, are com-
monly used for glycoprotein detection. When incubated with
the battery of lectins listed in Table 1, B-tau and N-tau were
not stained (Fig. 1F^I, lanes 1^2). In contrast, AD-tau, AD P-
tau and PHF-tau were all positively stained with lectins (Fig.
1F^I, lanes 3^5). Each of the tau preparations displayed dif-
ferent staining patterns with the lectins employed, suggesting
that these di¡erent forms of tau were di¡erentially glycosylat-
ed. Based on the known speci¢cities of the lectins (Table 1),
these data (Fig. 1F^I) suggested that all of the three pools of
tau isolated from AD brain contained mannose (detected by
GNA, Fig. 1H), galactose (detected by APA, Fig. 1F) and
sialic acid (detected by SNA + MAA, Fig. 1I). In addition,
AD-tau and AD P-tau also contained galactose-L1,3/1,4-N-
acetylglucosamine (detected by DSA, Fig. 1G). As compared
with AD P-tau, PHF-tau had much weaker staining with lec-
tins DSA and GNA (Fig. 1G,H). To rule out the possibility of
non-speci¢c cross-reaction with these lectins, we examined
these tau preparations with several other lectins that recognize
the same sugar moieties as those shown in Fig. 1. These lectins
include ABA, ConA, RCA and LCA (Table 1). Similar results
were obtained with di¡erent lectins that recognize the same
sugar moieties (data not shown). None of these ¢ve tau prep-
arations were stained with the lectins UEA I, TGP or ECA
(data not shown), suggesting that these proteins did not con-
tain any fucose or galactose-L1,4-N-acetylgalactosamine.
The major lectin-positive bands as seen in Fig. 1 had higher
apparent molecular weights than the most dominant tau iso-
forms seen on blots detected with antibody 92e to total tau.
This might be because the aberrant glycosylation mainly oc-
curs in an aggregated form of tau in AD brain or the lectin
staining was due to glycoproteins other than tau present as
contaminants in these tau preparations. To con¢rm the aber-
rant glycosylation of AD-tau and AD P-tau, we puri¢ed non-
aggregated AD-tau and AD P-tau from three individual AD
brains using Seize1 X Immunoprecipitation kit. This tech-
nique enabled puri¢cation of tau free from contaminating
proteins as well as the antibody that is also a glycoprotein.
The contamination of AD P-tau in these AD-tau preparations
was excluded by Western blot analyses using anti-tau[pS199]
and anti-tau[pS396], which react only with AD P-tau (Fig.
2Aa,b). Lectin staining indicated positive for AD-tau (Fig.
2Ac^f, lanes 1^3) and AD P-tau (lanes 4^6), although the
staining for AD-tau was weaker than that of AD P-tau.
One of the three AD-tau preparations did not display positive
staining with APA, RCA or SNA/MAA (Fig. 2A, lane 1),
indicating signi¢cant variations of the tau glycosylation be-
tween individual samples. These variations were most likely
due to the heterogeneity of tau glycosylation among these
Fig. 1. Western and lectin blot analyses of various pools of tau. Iso-
lated tau preparations (3.0 Wg/lane) were separated by 10% SDS^
PAGE and the polypeptides were then transferred onto PVDF
membranes. The blots were developed either with tau antibodies or
with lectins. Lanes 1^5 are B-tau, N-tau, AD-tau, AD P-tau and
PHF-tau, respectively. Antibody 92e (A) was used to detect the to-
tal amount of tau loaded in each lane. Several phosphorylation-de-
pendent tau antibodies (B^E) were used to verify the phosphoryla-
tion state of tau. Various lectins (F^I) were employed to identify
glycosylation and the speci¢c sugar moieties. At the left side of each
blot, the arrow indicates the top of the separating gel, and the short
bars indicate the position of molecular mass markers (200, 98, 67
and 43 kDa, respectively).
FEBS 25717 8-2-02
F. Liu et al./FEBS Letters 512 (2002) 101^106 103
individuals, which is a well-known characteristic of protein
glycosylation [27,28].
We compared the lectin-positive bands with the tau anti-
body R134d-positive bands of the same lane and found that
the lectin-positive bands matched the majority of the R134d-
positive bands (Fig. 2B). When the tau blots were incubated
with lectins in the presence of the speci¢c competitive mono-
or disaccharides, the lectin staining was abolished (data not
shown). These results suggested that the lectin staining was
the result of the speci¢c binding of the lectins to the speci¢c
sugar moieties of tau, rather than non-speci¢c binding of the
lectins to the protein. To further con¢rm the glycosylation of
AD-tau, we incubated AD-tau with DSA- and RCA-conju-
gated agarose beads, followed by Western blotting of the lec-
tin-a⁄nity-precipitated proteins. We found that AD-tau was
a⁄nity-precipitated by these lectins as determined with tau
antibody R134d (data not shown). These data indicated that
though it is not abnormally hyperphosphorylated, AD-tau is
aberrantly glycosylated in AD brain.
3.2. Tau is mainly modi¢ed by galactose, glucose, mannose,
GlcNAc and sialic acid with N-linked glycosylation in
AD brain
The monosaccharide composition of the immunoa⁄nity-
puri¢ed PHF-tau and AD P-tau was analyzed by Dionex
HPAEC. We found that the PHF-tau contained galactose,
glucose, mannose, GlcNAc, sialic acid and GalNAc, but not
fucose moieties. Some of these monosaccharides were below
the expected stoichiometry level (Table 2), indicating that only
some of the PHF-tau molecules were glycosylated. This is in
agreement with the lectin staining that only some of the tau
polypeptides contained glycans. It is noted that the PHF-tau
contained minimal GalNAc, a component of the core disac-
charide of most O-linked oligosaccharides [29], suggesting that
the oligosaccharides might be linked to tau mainly through N-
linkage, but not O-linkage [30]. The lack of staining of the
immunoa⁄nity-puri¢ed AD-tau, AD P-tau and PHF-tau by
PNA (data not shown) also indicated that tau in AD brain
does not contain GalL1,3GalNAc, the core disaccharide of
most O-linked oligosaccharides [29]. Furthermore, AD-tau
could not be a⁄nity-precipitated with PNA-conjugated aga-
rose (data not shown). These ¢ndings together suggested that
tau isolated from AD brain might mainly contain N-linked
oligosaccharides.
3.3. Tau phosphorylation modulates its subsequent
phosphorylation
We have investigated the pathophysiological signi¢cance of
the tau glycosylation by examining its e¡ect on tau phosphor-
ylation. The deglycosylated AD-tau and the control-treated
AD-tau were incubated in parallel with PKA in the presence
Fig. 2. Detection of glycosylation of immunoa⁄nity-puri¢ed AD-
tau and AD P-tau. A: Immunoa⁄nity-puri¢ed AD-tau (lanes 1^3)
and AD P-tau (lanes 4^6) from three AD brains (tau in lanes 1 and
4, 2 and 5, and 3 and 6 were from the same brain, respectively)
were subjected to Western and lectin blotting. The phosphorylation-
dependent antibodies Tau-1 (a) and a mixture of anti-tau[pS199] and
anti-tau[pS396] (b) were used for detecting AD-tau and AD P-tau,
respectively. The same samples were also subjected to detection for
speci¢c sugar moieties recognized by various lectins as indicated at
right side of each blot (c^f). At the left of each blot, the bars indi-
cate the positions of molecular mass markers in kDa. B: The a⁄n-
ity-puri¢ed AD P-tau was resolved by 10% SDS^PAGE and blotted
onto PVDF membrane. Each lane of the AD P-tau was cut at the
center into two strips. Half of each lane (one strip) was stained with
R134d to total tau. The other half was developed with lectin APA
(a), RCA (b), or a mixture of SNA and MAA (c). The molecular
mass markers in kDa are indicated at the left of the blots.
Table 2
Monosaccharide composition of PHF-tau
Monosaccharide Stoichiometry (mol/mol of tau)
Galactose 2.9
Glucose 1.6
Mannose 0.6
GlcNAc 0.4
Sialic acid 0.2
GalNAc 0.1
Fucose 0.0
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of [32P]ATP and the tau phosphorylation was monitored by
measuring 32P incorporation to the protein. We found that the
deglycosylated AD-tau was phosphorylated at a lower rate
and to a smaller extent as compared with the control-treated
AD-tau (Fig. 3A). During 170 min incubation, 0.9 and 1.7
mol Pi/mol of tau were incorporated in the deglycosylated
and the control-treated AD-tau, respectively. Under the
same conditions, recombinant human tau441 and bovine brain
tau were phosphorylated to a stoichiometry of approximately
1.2 mol Pi/mol of tau (data not shown).
We also used site-speci¢c and phosphorylation-dependent
antibodies to examine the phosphorylation of AD-tau at
Ser214, Ser262/Ser356 and Ser409, which are among the six
phosphorylation sites of tau catalyzed by PKA [31,32]. For
this purpose, the deglycosylated and control-treated AD-tau
were incubated with PKA in the presence of non-radioactive
ATP and the tau phosphorylation was detected by a radio-
immuno-dot-blot assay that selectively measures the phos-
phorylation of tau at Ser214, Ser262 and Ser409. Similar to
the data observed with 32P incorporation, the deglycosylated
AD-tau was phosphorylated at a lower rate and to a smaller
extent than the control-treated AD-tau (Fig. 3B). These re-
sults suggested that the tau glycosylation might facilitate tau
phosphorylation by PKA.
4. Discussion
In the present study, we have found that unlike N-tau, AD-
tau, which is known to be normal with respect to its phos-
phorylation state and biological activity, is glycosylated.
Monosaccharide composition analyses and speci¢c lectin
staining suggested that tau in AD brain is glycosylated mainly
through N-linkage. This is in agreement with a recent report
in which several N-linked oligosaccharides was identi¢ed in
AD P-tau and PHF-tau [15]. Our data suggest that the aber-
rant modi¢cation of tau by glycosylation probably occurs at
an early stage, i.e. before the abnormal hyperphosphorylation
and loss of its biological activity. Thus, the tau pathology
might begin at a much earlier stage than previously thought
in AD. This ¢nding may open a new avenue to investigate the
pathogenesis of tau pathology in AD. Since AD-tau is active
in binding to microtubules and stimulating microtubule as-
sembly [9], the glycosylation of tau does not appear to directly
a¡ect tau’s biological activity. However, our results suggest
that the tau glycosylation facilitates PKA-catalyzed tau phos-
phorylation. PKA is one of the tau kinases [31,33,34] and the
phosphorylation of tau by PKA accelerates subsequent Alz-
heimer-like hyperphosphorylation of tau catalyzed by glyco-
gen synthase kinase-3L [35,36]. According to the present ¢nd-
ings, we hypothesize that tau glycosylation is an early
abnormality that facilitates its abnormal hyperphosphoryla-
tion in AD. It has been reported that the activity of the major
tau phosphatase, protein phosphatase 2A [23,37,38], is de-
creased in AD brain as compared with age-matched controls
[39,40]. Hence, the abnormal hyperphosphorylation of tau in
AD brain might be the consequence of multiple metabolic
abnormalities including the imbalance of the protein kinase
and phosphatase activities, and the aberrant tau glycosylation.
In addition, the aberrant glycosylation may coordinate with
hyperphosphorylation to facilitate the aggregation of tau into
PHF or stabilize the ¢lamentous structure of PHF. Enzymatic
deglycosylation of PHF was shown to untwist PHF into
straight ¢laments 2.5 þ 0.5 nm in diameter [12].
We have noticed that AD P-tau appears to be glycosylated
to a higher extent than AD-tau (Figs. 1 and 2). The more
glycans in AD P-tau might partially contribute to the hyper-
phosphorylation of these tau molecules. The glycosylated tau
is more di⁄cult to be dephosphorylated in vitro by protein
phosphatase 2A (unpublished observation). We also noticed
the aberrant glycosylation on only some of the tau molecules
and the individual variation. Thus, glycosylation might pro-
mote but might not be required for the abnormal hyperphos-
phorylation of tau. A recent study has shown that in vitro
abnormal hyperphosphorylation of recombinant tau is su⁄-
cient to cause its self-assembly into PHF [41]. The various
extents and sugar compositions of the aberrant glycosylation
might a¡ect the subsequent phosphorylation of tau di¡erently.
A detailed kinetic study remains to be carried out to elucidate
the site- and sugar-speci¢c correlation between glycosylation
and phosphorylation of tau.
Previously, it was shown that B-tau is modi¢ed by a mono-
saccharide, GlcNAc, via GlcNAcylation [16]. Whether human
tau is also GlcNAcylated is not yet known. GlcNAcylation is
a special type of dynamic glycosylation that is di¡erent from
classical protein glycosylation. The latter normally occurs in
the rough endoplasmic reticulum and Golgi apparatus, and is
restricted to membrane-bound and secreted proteins. Tau is a
Fig. 3. E¡ect of deglycosylation on phosphorylation of tau by
PKA. A: The deglycosylated (b) and control-treated (a) AD-taus
as substrates were incubated with [Q-32P]ATP and PKA in a phos-
phorylation bu¡er at 30‡C for various periods. The 32P incorpora-
tion was determined by counting the radioactivity of the AD-tau
after removing the free [32P]ATP by paper chromatography. B: The
deglycosylated AD-tau (b) and the control-treated AD-tau (a) were
incubated with PKA as in (A) except non-radioactive ATP was
used instead of [32P]ATP. The phosphorylation of tau in the reac-
tion mixture was detected by a radioimmuno-dot-blot assay using a
mixture of three phosphorylation-dependent antibodies, anti-
tau[pS214], anti-tau[pS262] and anti-tau[pS409], which detect the phos-
phorylation of tau at the corresponding sites. A representative result
of three experiments is shown.
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cytosolic protein and does not contain the signal peptides
required for entering the endoplasmic reticulum. It is cur-
rently not known how tau is glycosylated. A possibility is
that glycosyltransferases that transfer sugar moieties to pro-
teins leak from the endoplasmic reticulum and Golgi appara-
tus into cytoplasmic compartment of the a¡ected neurons in
AD brain. Abnormalities of these subcellular organelles of
neurons have been reported in AD [42]. Alternatively, glyco-
sylation of tau in AD brain might be a consequence of the
association of tau protein with rough endoplasmic reticulum
and plasma membrane [43,44], and abnormalities of mem-
brane phospholipids [45] and membrane £uidity [46] have
been described in AD brain. Due to one or more of these
anomalies, tau might become accessible to speci¢c glycosyl-
transferases and be glycosylated. Aberrations in the molecular
topology of neuronal membranes might be involved in the
pathogenesis of AD [47].
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